by TD Admin | Aug 21, 2019 | Blog Posts
Bladder cancer is the sixth most commonly diagnosed cancer in the European Union. Here, we evaluate the performance of a novel, commercially available enzyme-linked immunosorbent assay utilising MCM5 antibodies (ADXBLADDER; Arquer Diagnostics Ltd, Sunderland, UK) for...
by Tim Dudderidge | Apr 3, 2019 | Blog Posts
The FORECAST study has been assessing men with recurrent prostate cancer after prior radiotherapy. The study looked at the diagnosis / staging process to see whether a combination of MRI, PET-CT, Whole Body MRI and Bone scan could improve the detection of metastatic...
by Tim Dudderidge | Apr 3, 2019 | Blog Posts
The INDEX study has now completed recruitment. Its a landmark study in the making with the largest series of focal prostate HIFU treatments ever studied. Men with cancer on one side of the prostate who elected to have focal prostate HIFU have been studied and results...
by Tim Dudderidge | Apr 3, 2019 | Blog Posts
During my time as a Lecturer at UCL researching cancer markers I investigated the role of the cell-cycle protein Mcm5 in the field of urological cancer diagnosis. Since then the technology has been commercialised by Arquer diagnostics Ltd and I have led trials in both...
by Tim Dudderidge | Apr 3, 2019 | Blog Posts
The PROMIS study has changed the diagnostic pathway for prostate cancer completely. At UHS we recruited 50 men who agreed to the new Multiparametric MRI and then a thorough prostate biopsy which determined their cancer status with incredible accuracy. The results were...
